You are here

Better Health Literacy Seems To Boost Patient Satisfaction With Biosimilars

European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.

European researchers looked at arthritis’ patients reactions when being switched from etanercept or nfliximab.

There seems to be a relationship between a patient’s willingness to switch to a biosimilar and health literacy, according to study presented by Milada Cvancarova Smastuen and colleagues at the European League Against Rheumatism’s Annual European Congress of Rheumatology in June in Amsterdam. About one in five patients taking etanercept (Enbrel) or infliximab (Remicade) who were switched to less expensive biosimilars said that they were dissatisfied. But the study adds that the patients’ level of satisfaction with the switch was associated with health literacy, which researchers defined as being given sufficient and necessary information about their health.

Source: Center for Biosimilars

More Headlines

Conversely, Kids Who Need Drugs Go Untreated
May Reduce the Need for Open-Heart Surgery
NDEA, a Known Carcinogen, Discovered During FDA Testing
Cleared for Adults with Relapsed or Refractory Disease
Approved as Maintenance Treatment for Opioid Dependence
Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic
Study Uses Experimental Software to Decode Variations in Mood
Mixup with Losartan Discovered in Bottles